Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

Journal Articles

Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

Sunisa Kongkiatkamon, MD, Yasunobu Nagata, MD PhD, Vera Adema, PhD, Hassan Awada, MD, Misam Zawit, MD, Laila Terkawi, Simona Pagliuca, MD, Carmelo Gurnari, MD, Cassandra M Kerr, MS, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Yogenthiran Saunthararajah, MD, Bhumika J. Patel, MD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143210

Published: 2020

Journal Articles

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

Hassan Awada, MD, Arda Durmaz, Carmelo Gurnari, MD, Misam Zawit, MBBS, Sunisa Kongkiatkamon, MD, Simona Pagliuca, MD, Cassandra M. Kerr, MS, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139920

Published: 2020

Journal Articles

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Lina Benajiba, MD PhD, Hetty E. Carraway, MD MBA, Nada Hamad, MB.BS, FRACP, FRCPA, Eytan M. Stein, MD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Amy Burroughs, Scott Harris, Hayley Lane, Dorothy D. Nguyen, MD, Monic Stuart, MD MPH, Jesse Vargas, PhD, Alexandre Puissant, PhD, Kimberly Stegmaier, MD, Courtney D. DiNardo, MD MSCE

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140636

Published: 2020

Journal Articles

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Eric Parsons, RN, Jenna Thomas, Hetty E. Carraway, MD MBA, Dale Grabowski, BS, Yihong Guan, PhD, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Anjali S Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139494

Published: 2020

Journal Articles

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Swapna Thota, MD, Terrence J Bradley, MD, Hetty E. Carraway, MD MBA, Elizabeth A. Griffiths, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141393

Published: 2020

Journal Articles

Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs . Myeloid Neoplasia

Misam Zawit, MBBS, Jibran Durrani, MD, Wenyi Shen, MD, Vera Adema, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Laila Terkawi, Bhumika J. Patel, MD, Valeria Visconte, PhD, Hetty E. Carraway, MD MBA, Thomas LaFramboise, PhD, Seth J. Corey, MD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-142586

Published: 2020

Journal Articles

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139013

Published: 2020

Journal Articles

The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH

Carmelo Gurnari, MD, Simona Pagliuca, MD, Bhumika J. Patel, MD, Hassan Awada, MD, Cassandra M Kerr, MS, Wenyi Shen, MD, Sunisa Kongkiatkamon, MD, Laila Terkawi, Misam Zawit, MBBS, Jibran Durrani, MD, Valeria Visconte, PhD, Seth J. Corey, MD, Maria Teresa Voso, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140045

Published: 2020

Journal Articles

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

David H. Henry, MD, John Glaspy, MD MPH, Rosemary Anne Harrup, Moshe Mittelman, MD, Amy Zhou, MD, Hetty E. Carraway, MD MBA, Charles Bradley, PhD, Gopal Saha, MD, Pamela Bartels, Robert Leong, Peony Yu, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142499

Published: 2020

Journal Articles

Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

Carmelo Gurnari, MD, Vera Adema, PhD, Hassan Awada, MD, Simona Pagliuca, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Thomas Laframboise, PhD, Valeria Visconte, PhD, Maria Teresa Voso, MD, Mikkael A. Sekeres, MD MS, Hetty E. Carraway, MD MBA, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140058

Published: 2020

Journal Articles

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

Simona Pagliuca, MD, Carmelo Gurnari, MD, Sanghee Hong, MD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, MD, Hassan Awada, MD, Ashwin Kishtagari, MBBS, Misam Zawit, MBBS, Laila Terkawi, Valeria Visconte, PhD, Eric D. Hsi, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-143242

Published: 2020

Journal Articles

The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia

Hassan Awada, MD, Cassandra M. Kerr, MS, Vera Adema, PhD, Carmelo Gurnari, MD, Simona Pagliuca, MD, Heesun J. Rogers, MD PhD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-139528

Published: 2020

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Jibran Durrani, Hassan Awada, MD, Wenyi Shen, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Sunisa Kongkiatkamon, Ashwin Kishtagari, MBBS, Samuel Li, Yasunobu Nagata, MD PhD, Sanghee Hong, MD, Aziz Nazha, MD, Bhumika J. Patel, MD, Yogenthiran Saunthararajah, MD, Hetty E. Carraway, MD MBA, Valeria Visconte, PhD, Seth J. Corey, MD, Mikkael A. Sekeres, MD MS, Thomas Laframboise, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 452.

https://doi.org/10.1182/blood-2019-130142

Published: 2019

Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2019) 134 (Supplement_1): 673.

https://doi.org/10.1182/blood-2019-123854

Published: 2019

Journal Articles

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 16.

https://doi.org/10.1182/blood-2019-130319

Published: 2019

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Hassan Awada, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Arda Durmaz, Sanghee Hong, MD, Cassandra M Kerr, MS, Vera Adema, PhD, Yihong Guan, PhD, Sonia Sandhu, Aziz Nazha, MD, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1405.

https://doi.org/10.1182/blood-2019-131953

Published: 2019

NARROW

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

A Multi-Center Open-Labeled Phase II Study of Intensive Salvage Therapy Followed By Enasidenib Maintenance for Patients with Relapsed/Refractory IDH2 mutant AML

Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs . Myeloid Neoplasia

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH

Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels

Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations

The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

FA Gene Carrier Status Predisposes to Myeloid Neoplasms and Bone Marrow Failure in Adults

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Mutational Patterns and Clonal Architecture of Therapy-Related Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only